Los puntos clave no están disponibles para este artículo en este momento.
This Viewpoint discusses a recent federal court decision that invaliated the Food and Drug Administration’s (FDA) approval of mifepristone, a drug used to end pregnancies and manage miscarriage when used with misoprostol, and how that decision challenges the legitimacy and independence of the FDA.
Abbe R. Gluck (Fri,) studied this question.